Trial Profile
A Phase 1/2 Study Of SKI-606 Administered As A Single Agent In Japanese Subjects With Philadelphia Chromosome Positive Leukemias
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 04 Aug 2023
Price :
$35
*
At a glance
- Drugs Bosutinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 15 Jun 2023 Results of post-hoc pooled analysis of B1871006 (NCT00261846), B1871007 (NCT00811070), B1871039 (NCT02228382, BYOND) B1871048 (NCT03128411), B1871008 (NCT00574873) & (B1871040, NCT01903733) assessing effect of BMI on the safety of bosutinib in patients with previously treated or newly diagnosed CML, presented at the 28th Congress of the European Haematology Association.
- 10 Aug 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 15 Jul 2014 Planned End Date changed from 1 Sep 2014 to 1 May 2015 as reported by ClinicalTrials.gov.